Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12070500

Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibi

VACCINEX, INC. · Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054557

Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12016860

Combination therapies with Cbl-b inhibitor compounds

NURIX THERAPEUTICS, INC. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12000829

Selection of patients for combination therapy

Syndax Pharmaceuticals, Inc. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11981921

TIL expansion processes using specific cytokine combinations and/or AKTi treatment

Iovance Biotherapeutics, Inc. · Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11980633

Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitor

Vertex Pharmaceuticals Incorporated · Granted Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11974989

Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

VTV THERAPEUTICS LLC · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11964016

Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11938124

Combination therapy for treatment of cancer

PMV PHARMACEUTICALS, INC. · Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11931463

All-in-one fixed-dose combination for treating Helicobacter pylori infection

RedHill Biopharma Ltd. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11890289

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat ad

Corcept Therapeutics Incorporated · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11890285

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11883492

Combination treatment of chemoresistant cancers

The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11872200

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA co

The Regents of the University of California · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11857531

Combination mast cell inhibition for treatment of BPH/LUTS

Northwestern University · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833136

Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

VTV THERAPEUTICS LLC · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11793819

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11771752

Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone

Prime Bio, Inc. · Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11744816

Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of t

Esperion Therapeutics, Inc. · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11746152

Methods of cancer treatment and therapy using a combination of antibodies that bind glycos

The Board of Regents of the University of Texas System · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11714089

Combination of markers for diagnosing cancer

The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11712474

Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibi

Regen Biopharma, Inc. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679112

Cancer treatments using combinations of CDK and ERK inhibitors

Biomed Valley Discoveries, Inc. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11666574

Combination therapy involving diaryl macrocyclic compounds

TURNING POINT THERAPEUTICS, INC. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted